Prestige Wealth Management Group LLC Acquires 115 Shares of Amgen Inc. (NASDAQ:AMGN)

Share on StockTwits

Prestige Wealth Management Group LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 13.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,003 shares of the medical research company’s stock after acquiring an additional 115 shares during the quarter. Prestige Wealth Management Group LLC’s holdings in Amgen were worth $255,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Pure Financial Advisors Inc. raised its holdings in Amgen by 2.8% in the second quarter. Pure Financial Advisors Inc. now owns 1,469 shares of the medical research company’s stock worth $346,000 after purchasing an additional 40 shares during the period. Carroll Financial Associates Inc. raised its holdings in shares of Amgen by 0.5% during the third quarter. Carroll Financial Associates Inc. now owns 7,574 shares of the medical research company’s stock worth $1,925,000 after acquiring an additional 41 shares during the period. Price Wealth LLC raised its holdings in shares of Amgen by 42.9% during the second quarter. Price Wealth LLC now owns 140 shares of the medical research company’s stock worth $33,000 after acquiring an additional 42 shares during the period. FCG Advisors LLC raised its holdings in shares of Amgen by 3.8% during the second quarter. FCG Advisors LLC now owns 1,162 shares of the medical research company’s stock worth $274,000 after acquiring an additional 42 shares during the period. Finally, AFT Forsyth AND Company Inc. raised its holdings in shares of Amgen by 1.0% during the second quarter. AFT Forsyth AND Company Inc. now owns 4,465 shares of the medical research company’s stock worth $1,053,000 after acquiring an additional 45 shares during the period. 75.23% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director Ronald D. Sugar sold 1,000 shares of Amgen stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $241.02, for a total transaction of $241,020.00. Also, Director R Sanders Williams sold 250 shares of Amgen stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $242.95, for a total transaction of $60,737.50. Following the sale, the director now directly owns 5,159 shares of the company’s stock, valued at approximately $1,253,379.05. The disclosure for this sale can be found here. Insiders own 0.36% of the company’s stock.

Shares of AMGN traded down $2.27 during midday trading on Monday, reaching $224.89. The stock had a trading volume of 3,085,969 shares, compared to its average volume of 2,869,839. The firm has a 50 day simple moving average of $243.46 and a 200-day simple moving average of $238.88. Amgen Inc. has a one year low of $177.05 and a one year high of $264.97. The firm has a market cap of $131.72 billion, a PE ratio of 18.37, a P/E/G ratio of 2.01 and a beta of 0.81. The company has a current ratio of 2.18, a quick ratio of 1.81 and a debt-to-equity ratio of 3.20.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.81 by $0.44. The company had revenue of $6.21 billion during the quarter, compared to the consensus estimate of $6.19 billion. Amgen had a net margin of 30.04% and a return on equity of 91.98%. The company’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the firm posted $3.97 EPS. As a group, research analysts forecast that Amgen Inc. will post 15.65 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Monday, November 16th will be issued a dividend of $1.60 per share. This represents a $6.40 annualized dividend and a dividend yield of 2.85%. The ex-dividend date of this dividend is Friday, November 13th. Amgen’s payout ratio is 43.18%.

A number of equities research analysts recently commented on the stock. Piper Sandler raised their price objective on shares of Amgen from $255.00 to $270.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. Wells Fargo & Company raised their price objective on shares of Amgen from $237.00 to $247.00 and gave the stock an “in-line” rating in a report on Wednesday, July 29th. Truist upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Monday, October 12th. Barclays raised their price objective on shares of Amgen from $245.00 to $250.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 29th. Finally, SVB Leerink raised their target price on shares of Amgen from $253.00 to $261.00 and gave the company a “market perform” rating in a research report on Wednesday, July 29th. Three investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and sixteen have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $254.88.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease.

Recommended Story: What are Bollinger Bands?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.